Absci Corporation's ABS-201 Shows Promising Hair Loss Treatment Results, Analysts Expect Upside

Absci Corporation (NASDAQ:ABSI) has shown promise in hair loss treatment with its AI-designed antibody ABS-201. The drug targets prolactin receptors to promote hair growth and has shown potential to extend the active growth phase of hair follicles. Analysts see upside with a $7 price target and a significant market given that androgenetic alopecia affects approximately 80 million Americans.